Disintegrin variants that bind specifically to one or more of a51 and av integrins such as a1 a3 a5 a6 and a8 but with reduced binding activity to aIIb3 are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an av integrin or an a51 integrin.